Multidrug-resistant (MDR) bacteria pose a grave concern to global health. This 2 problem is further aggravated by a lack of new and effective antibiotics and 3 countermeasure platforms that can sustain the creation of novel antimicrobials in 4 the wake of new outbreaks or evolution of resistance to antibiotics. To address 5 this, we have developed a Facile Accelerated Specific Therapeutic (FAST) platform 6 that can develop effective therapies against MDR bacteria within a week. Our FAST 7 platform combines four essential modules-design, build, test, and delivery-of drug 8 development cycle. The design module comprises a bioinformatics toolbox that 9 predicts sequence-specific peptide nucleic acids (PNAs) that target non-traditional 10 pathways and genes of bacteria in minutes. The build module constitutes in-situ 11 synthesis and validation of selected PNAs in less than four days and efficacy 12 testing within a day. As a proof of concept, these PNAs were tested against MDR 13 clinical isolates. Here we tested Enterobacteriaceae including carbapenem-14 resistant Escherichia coli, extended-spectrum beta-lactamase (ESBL) Klebsiella 15 pneumoniae, New Delhi Metallo-beta-lactamase-1 carrying Klebsiella pneumoniae 16 and MDR Salmonella enterica. PNAs showed significant growth inhibition for 82% 17 of treatments, with nearly 18% of the treatments leading to more than 97% 18 decrease. Further, these PNAs are capable of potentiating antibiotic activity in the 19 clinical isolates despite presence of cognate resistance genes. Finally, FAST offers 20 a novel delivery approach to overcome limited transport of PNAs into mammalian 21 cells to clear intracellular infections. This method relies on repurposing the 22 bacterial Type III secretion system in conjunction with a kill switch that is effective 23 at eliminating 99.6% of an intracellular Salmonella infection in human epithelial 24 cells. Our findings demonstrate the potential of the FAST platform in treating MDR 25 bacteria in a rapid and effective manner.
then synthesized, purified, and tested in parallel on a panel of multidrug-resistant (MDR) 23 clinical isolates to validate the toolbox's predictions. These results can then be recycled 24 to the PNA Finder toolbox to improve upon specificity predictions. Finally, promising PNAs 25 are delivered to treat intracellular infections of bacteria. 26 The PNA Finder bioinformatics toolbox offers the functions Get Sequences and 27 Find Off-Targets, which comprise automated workflows that combine custom Python 2.7 28 scripts with the alignment and analysis programs Bowtie 2 27 , SAMTools 28 , and 29 BEDTools 29 . Get Sequences is used to create a library of PNA candidate sequences that 30 target the mRNA translation start codons of a user-defined set of genes. The function 1 takes a list of gene IDs and searches a genome annotation file for matches, which can 2 then be used to extract nucleotide sequences from a corresponding genome assembly. 3 Additionally, Get Sequences provides sequence warnings for PNA solubility and self-4 complementarity issues, as well as a protein interaction network analysis via the STRING 5 database 30 . The PNA sequences provided by Get Sequences are used as inputs for the 6 Find Off-Targets function, which searches for incidental inhibitory alignments by 7 searching a non-target genome for highly similar sequences-1-bp mismatch or less-8 within a 20 nucleotide range of the start codon 26 . This function allows for the design of 9 highly specific PNAs that target only the desired gene in the specific pathogens of interest, 10 while avoiding broad inhibitory action against other pathogens, the human microbiome, 11 and the human transcriptome. 12 In this study we applied the FAST platform to the creation of PNA antibiotics for 13 clinical isolates of five MDR Enterobacteriaceae isolates: two Escherichia coli isolates, 14 two Klebsiella pneumoniae isolates, and one Salmonella enterica serovar Typhimurium 15 isolate. To design the set of candidate sequences, the Get Sequences tool was used with 16 a list of 296 essential and 4,090 non-essential E. coli genes, as well as the genome 17 assembly and annotations for reference strain E. coli MG1655 ( Fig. 2A) . The Find Targets tool was used with this list to find off-targets within the E. coli genome, in order 19 to avoid inhibition of unintended genes that could confound results. After filtering all PNA 20 with 0-bp mismatch off-targets we were left with a library of 260 PNA candidates targeting 21 essential genes and 3,524 candidates targeting non-essential genes within E. coli. We 22 ran this list of candidates through Find Off-Targets twice: first with K. pneumoniae (KPN) 23 reference genome MGH 78578, then Salmonella enterica serovar Typhimurium (STm) 24 reference genome SL1344. The alignments of PNA candidates to these genomes were 25 analyzed to determine which would be predicted to target K. pneumoniae and S. 26 Typhimurium genes that are analogous to the original E. coli gene target. From this 27 analysis we identified 101 essential and 278 non-essential PNA candidates that showed 28 target sequence homology between the three reference genomes. Finally, we eliminated 29 PNAs that were predicted by the Get Sequences tool to have low solubility or exhibit self-30 complementarity, resulting in a list of 71 essential and 243 non-essential target gene 1 candidates. The duration of this computational design pipeline was under ten minutes. 2 For testing with the MDR isolates, we first selected two novel gene targets with 3 functions related to those inhibited by conventional antibiotics: gyrB 31 (protein gyrase 4 subunit B) and rpsD 32 (30S ribosomal protein S4) ( Fig. 2A) . These genes contribute to 5 pathways similar to those inhibited by fluoroquinolones and tetracycline/aminoglycosides 6 respectively. We then chose three non-conventional antibiotic gene targets: ffh 33 (signal 7 recognition particle protein, essential), lexA 34 (SOS response repressor protein, 8 essential), and acrA 35 (transmembrane transport protein, non-essential). We also 9 selected PNA targets that were not from the 71 essential or 243 non-essential candidates 10 with homology in all three MDR species to demonstrate the PNA's species selectivity. We 11 selected one essential and two non-essential targets in non-traditional pathways specific 12 to only E. coli: folC 36 (essential, H2 folate synthetase), csgD 37 (curli fimbriae expression, 13 non-essential), and fnr 38 (anaerobic metabolism, non-essential). Additionally, we chose 14 to target recA 39 (SOS double stranded break repair, non-essential) because it shows 15 homology to E. coli and Salmonella but not KPN.
16
The efficiency of the PNA Finder tool reduces the requisite time to obtain antisense 17 antibiotic sequences, and the discovery period becomes limited merely by the duration of 18 the FAST platform's synthesis, purification, and testing. Prior to testing on MDR clinical 19 isolates, we selected two of this set of PNA, α-rpsD and α-lexA, to evaluate how quickly 20 these latter steps of the FAST pipeline could be accomplished. It was determined that 21 solid-phase synthesis, using Fmoc chemistry at a 10-micromole scale, of the 23-residue 22 peptides (see Methods, Supplemental S1) required less than three days. This was 23 followed by purification using High Performance Liquid Chromatography (HPLC), 24 confirmation using Liquid chromatography-mass spectrometry (LC-MS), and 25 lyophilization; this process required less than seven hours ( Fig. 2B ). Testing required an 26 additional 24-hour experiment and validated the predicted toxicity of PNA against their 27 essential gene targets in E. coli reference strain MG1655 ( Fig. S2 & S3 ).
28
Prior to treatment of MDR clinical isolates with the PNA designed by the FAST 1 platform, we characterized both the phenotypic and genotypic resistance profiles of the 2 five MDR clinical isolates that were obtained. These isolates included a carbapenem- Table S1 ). We found all isolates to have resistance to two 9 or more antibiotics, with CRE E. coli showing resistance to all nine antibiotics tested.
10
Genome sequencing showed all of the clinical isolates to have at least two unique 11 antibiotic resistance genes, and at least one β-lactamase gene ( Fig. 2C , Table S2 ). The 12 sequencing also allowed us to confirm the presence of each antisense target sequence 13 in each isolate. Additionally, Find Off-Targets was used to search these genome 14 assemblies for off-targets around the start codon. Among all PNA and MDR strains we 15 predicted only one PNA to have a single inhibitory off-target in each clinical isolate, α- Table S3 ).
18
Each PNA was conjugated to the cell-penetrating peptide (CPP) (KFF)3K to 19 enhance transmembrane transport 22, 23, 41, 42 and administered to clinical isolates at a 10 20 µM concentration, based on the minimum inhibitory concentration (MIC) observed in E. 21 coli MG1655, to assess the toxicity of each as a monotherapy (Fig. S3 ). Inhibition was 22 compared to a scrambled sequence PNA (α-nonsense) as a control. Eighteen out of 34 23 treatments that showed homology to target clinical isolates demonstrated at least 50% 24 growth inhibition, as shown in Fig. 2D -F. The PNA α-rpsD was found to be the most 25 successful monotherapy, causing a greater than 50% growth reduction in all five clinical 26 isolates ( Fig. 2D&E, Fig. S5 ). α-gyrB, α-lexA, and α-ffh were found to significantly inhibit 27 growth in all clinical isolates but NDM-1 KPN (p-val< 0.05). Of the PNAs targeted to only 28 E. coli, α-folC ( Fig. 2E) , and α-csgD ( Fig. 2F ), successfully inhibited growth (p-val < 0.05) 29 in both E. coli isolates, whereas α-fnr ( Fig. S5 ) was effective against only the CRE E. coli 30 strain. α-recA, which is specific to STm and E. coli, was effective against both E. coli 31 strains and MDR STm. PNA treatments demonstrated high selectivity to their target 1 strains. Of the 45 total treatments, 34 were predicted to have homology to the clinical 2 isolate tested and eleven did not. Seven out of eleven PNA treatments without sequence 3 homology to the clinical isolate showed no growth reduction; the remaining four showed 4 less than 10% growth inhibition ( Fig. S5 ). Of the 34 clinical isolate-PNA pairs predicated 5 to have homology 28 showed significant growth inhibition, with 6 monotherapy treatments 6 reducing growth by more than 97% (Fig. 2F, Fig. S5 ). This success rate is remarkable 7 given the high difficulty in treating these strains with conventional antibiotic strategies.
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In analyzing these results, we looked for correlations between growth inhibition 9 and each gene target's corresponding mRNA abundance level, secondary structure, and 10 protein network interactions ( Fig. S6, S7 ). Though a trend has been suggested in previous 11 antisense antibiotic research 43 , we did not identify any correlation between predicted 12 secondary structure and growth inhibition; nor did we identify a correlation with mRNA 13 abundance. We observed a significant correlation (Pearson correlation coefficient 14 r=0.908, p-val<0.001) between growth inhibition and protein interaction network 15 connectedness denoted by average node degree-as identified by STRING protein 16 network analysis 30 (Fig. 3A) . The positive correlation indicates that the more 17 interconnected a network is the more susceptible it is to PNA treatment. Conversely, 18 loosely connected protein interaction networks (low node degree) showed weaker 19 monotherapy effects. 20 We tested PNAs that showed minimal to moderate growth inhibition in Table S2 ), yet it was still possible to re-sensitize it to the antibiotics at their CLSI 2 breakpoints (Table S1 ). We also identified significant synergistic interaction in ESBL KPN 3 between the PNAs α-ffh, α-lexA, and α-gyrB (10 µM) and tetracycline (2 µg/mL, Fig. 3J -4 M, Fig. S8 ). Our data showed a negative correlation (r = -0.3017, p-val<0.05, Fig. 3N ) 5 between the degree of synergy and average node degree, indicating that targeting genes 6 that have less interconnected protein interaction networks could give rise to synergy with 7 antibiotics. Further, in contrast with previous research that showed a higher degree of 8 antibiotic synergy between antisense oligonucleotides and small molecule drugs when 9 the treatments targeted related pathways 45,46, , our results indicate that unrelated 10 mechanisms of inhibition can also result in combination effects in MDR pathogens. Our 11 data demonstrate that the FAST platform is capable of designing PNAs that can be highly 
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The final obstacle for PNA antibiotic viability that the FAST platform seeks to 18 address is the molecules' poor uptake into mammalian cells to treat mammalian 19 intracellular infections 47, 48 . Though conjugation to a CPP improves PNA transmembrane 20 transport in bacteria, transport into mammalian cells still remains limited, creating 21 challenges for in vivo application of the therapy. Though nanoparticle and lipoparticle 22 based approaches are being developed, these have challenges of poor tissue targeting 23 and lower stability 47 . To overcome some of these limitations, here we present a probiotic-24 based delivery approach for delivering antisense oligomers to infected mammalian cells.
25
In the delivery phase of the FAST platform, we present a first probiotic prototype for PNA 26 transport using the Type III secretion system (T3SS), a gram-negative bacterial machine 27 for invasion of the eukaryotic host cell 49,50 , combined with a lysis switch to release the 28 therapeutic.
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First, we sought to establish that a strain expressing the T3SS was capable of 1 transporting PNA-α-rpsD and α-lexA were chosen for this evaluation-into human 2 epithelial cells (HeLa). We confirmed that PNAs are not lethal to mammalian cells in the 3 range tested (Fig. S9 ). To confirm transport into mammalian cells we used the S. -4 Typhimurium strain SL1344, which expresses both the T3SS and green fluorescent 5 protein (GFP) 51 (the strain is referred to from here as STm-GFP). We examined transport growth by more than 60% in the T3SS-PNA conditions ( Fig 4B&C, Fig. S11 ), whereas 19 neither reduced infection in the naked PNA condition even though PNA was added 20 extracellularly for 18 hours as compared to the 45-minute co-incubation. The same 21 experiment was repeated in a different mammalian cell line, murine osteoblasts, with 22 reproducible results indicating it is not a unique phenomenon to a HeLa intracellular 23 infection ( Fig. S12 ). These results demonstrate that S. Typhimurium, expressing the 24 T3SS, can act as a delivery vessel of PNA into human epithelial cells. 25 We next engineered the STm-GFP strain to release PNA into the mammalian cell 26 to target a separate intracellular pathogen. We constructed a modified strain of STm-GFP 27 in which cell lysis can be induced by a holin-endolysin system 52 under the control of a 28 laciQ promoter (strain referred to as Delivery STm, Fig. S13 ) to treat a separate 29 intracellular pathogen, SL1344 expressing mCherry via a plasmid (strain referred to as 30 Target STm). This promoter had a lac operator downstream, which has been shown to 31 permit RNA polymerase readthrough even for tightly bound LacI proteins 53 , which 1 enabled basal expression sufficient to cause Holin-induced lysis in the absence of IPTG 2 induction ( Fig. S16 , S13B). To demonstrate assay generalizability, we used a different 3 PNA, α-recA, which was found to be lethal to STm-GFP at 10 µM ( Fig. S14 ). To treat a 4 separate intracellular infection, we allowed a 45-minute incubation period of the Delivery 5 STm-with either 10 µM α-recA (T3SS/Holin-PNA condition) or PBS (no treatment). The
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Target STm was incubated with PBS in parallel at equal cell densities. Delivery STm (with 7 or without PNA) was washed to remove any extracellular PNA and was then co-incubated 8 with the Target STm and HeLa cells, at a 4:1 ratio of Delivery to Target STm to achieve 9 a combined MOI of 10. The cultures were then washed again and incubated in 10 gentamicin-containing media for 18 hours to remove extracellular bacteria ( Fig. 4D ).
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Growth inhibition was measured by comparing the ratio of bacterial load after to before 12 infection, to account for any variability in initial bacterial load used for infection across 13 replicates. In the T3SS/Holin-PNA condition the intracellular load of the Target STm, 14 normalized to the Delivery STm load, was reduced by more than 99% compared to the 15 no PNA treatment condition. For two out of three biological replicates, the target strain 16 was completely eliminated across a range of MOI ( Fig. 4E, Fig. S15 & 16 ). In contrast, 17 when using a non-T3SS bacteria, E. coli MG1655, as the delivery strain, there was no 18 decrease in the Target STm load (Fig. 4F ). These data provide evidence that a 19 combination of the T3SS with a holin-endolysin system is an effective solution for the 20 delivery of PNA to treat intracellular infections, which remains a major hurdle in antisense 21 antibiotic treatments. Though S. Typhimurium is a pathogenic species, future work 22 towards the expression of the T3SS and holin-endolysin system within a probiotic species 23 will enable the efficient and safe transport of PNA into mammalian cells. 24 We have demonstrated the utility of the FAST platform to quickly and effectively 25 create PNA antibiotics, through the stages of design, synthesis, testing, and delivery.
26
Development of the FAST platform will help to create a much needed rapid and adaptive 27 countermeasure platform for accelerating the response to emergence of multidrug 28 resistance. The PNA Finder toolbox is capable of designing and screening hundreds of 29 PNA candidates simultaneously, in order to narrow down a list of sequences that 30 specifically target a harmful pathogen while avoiding targeting other species. The quick 31 design process allows for the creation and testing of potential antibiotic therapies in under 1 a week, and our results have demonstrated that this rational design process results in 2 much higher monotherapy success rates than conventional small molecule screening 3 pipelines 54 . Additionally, we demonstrate the utility of the FAST platform to create 4 antibiotics that are effective potentiators of conventional antibiotic activity, even in strains 5 with specifically identified to have resistance to small molecule drugs. Finally, we have 6 engineered a hybrid type III secretion/holin-endolysin system for effective therapeutic RNA complements were predicted to cause inhibition if they were located within 20 bases 20 of the mRNA start codon, based on previous work 26 . The Get Sequences function of the 21 PNA Finder toolbox was used to search for indicators of low solubility as described by 22 Gildea et al 56 , such as purine stretches greater than 5 bases, a purine content of greater 23 than 50%, or a guanine-peptide stretch of longer than 3 bases. The function also searched 24 for self-complementary sequences of greater than 5 bases. PNA target pathways were 25 identified using EcoCyc 57 and Regulon Database 58 . (Fig. S9 ). PNA was dissolved in H2O with 5% DMSO at 100 µM. Stocks were stored 9 at -20ºC for long-term and at 4ºC for working stocks to minimize freeze/thaw cycles. (Table S1) performed following the same procedure as the PNA growth assay mentioned above, 9 except for the addition of antibiotics tetracycline (2 µg/mL), gentamicin (4 µg/mL), 10 chloramphenicol (8 µg/mL), and meropenem (8 µg/mL) where appropriate.
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Combinatorial effects were evaluated using the Bliss Independence model 66 where the S 12 parameter defines a deviation from no interaction as is defined as:
Where ODAB is the OD at 24 hours in only antibiotic, OD0 is the OD at 24 hours without 14 treatment, ODPNA is the OD at 24 hours in only antisense-PNA at 10 µM, and ODAB, PNA is 15 the OD at 24 hours in a combination of antibiotic and antisense-PNA. S>0 is a deviation 16 towards synergy and S<0 is a deviation towards antagonism. S value significance was 17 determined using a two-way ANOVA, setting a threshold p-value of 0.05 for the first-order 18 interaction term. 
Double infection of HeLa cells and PNA treatment:
For the double infection of HeLa 1 cells with Target STm (SL1344-mCherry) and Delivery STm (SL1344-Holin) ( Fig. 4D-F of HeLa cells in 100 µL. PNA (100 µM) was added at 5 µL to 45 µL of bacteria and 7 incubated for 45 minutes at culturing conditions. Samples (10 µL) were taken at t=0 8 (before PNA addition) and t=45 min (after PNA treatment), and serially diluted, plated, 9 and grown for 16 hours at 37°C and CFU counted. Chemother. 51, 805-11 (2007) . Resistance. ACS Infect. Dis. 1, 253-263 (2015) . Gen. Genet. 187, 467-472 (1982) . Microbiol. 16, 45-55 (1995 Adv. Drug Deliv. Rev. 55, 267-280 (2003) . Candidates without off-targets are narrowed to those with homology among KPN and STm. Of 6 the final 71 essential gene candidates and 243 non-essential gene candidates that met the 7 thermodynamic requirements for experimental conditions, five and four PNAs targeting essential 8
and non-essential gene respectively were randomly chosen for assessment. Most of the PNAs 9
have homology to all three Enterobacteriaceae in this study, except α-folC, α-csgD, and α-fnr 10 which are designed to be specific to E. coli, and α-recA which is specific to E. coli and STm. PNAs 1 a-folC, a-ffh, a-lexA, a-acrA, a-recA, a-csgD, and a-fnr target novel pathways of metabolism, 2 signal recognition, stress response, transport, stress response, biofilm formation, and metabolism 3 respectively. PNAs a-gyrB and a-rpsD target novel genes in traditional antibiotic pathways. (B) 4
Following PNA solid-phase synthesis, the product is purified using HPLC (representative 5 chromatogram shown), verified by LCMS (representative spectra shown), and tested against a 6 lab strain of E. coli (MG1655, growth curves for a-lexA and a-rpsD shown Normalized growth (ratio of optical density of treatment to no treatment at 16 hours) of clinical 19
isolates in the presence of treatment with 10 µM of the indicated PNA. PNAs targeting essential 20
and non-essential genes and showing at least 50% growth inhibition are shown in panels E and 21 F respectively with significance (represented by an asterisk, p-val< 0.05) determined relative to 22
control nonsense PNA and no treatment respectively. All data shown are the average of 3 23 biological replicates with standard deviation shown as error bars. experimental setup for comparing PNA delivery into HeLa cells for treating an intracellular 5 infection of Salmonella enterica serovar Typhimurium, strain SL1344 expressing GFP (STm-1 GFP), using either the bacterial T3SS inherent to STm-GFP (Bottom, T3SS-PNA) or CPP 2 facilitated uptake (Top, Naked-PNA). All intracellular infection treatment experiments follow the 3 general protocol of 45-minute infection of HeLa cells 24 hours after seeding, 75-minute gentamicin 4 treatment to remove extracellular bacteria, and 18-hour incubation with treatment in media 5 containing gentamicin to ensure an only intracellular infection model. For comparing T3SS 6 delivered PNA to Naked-PNA infection was done using STm-GFP at an MOI of 10. For the T3SS-7
PNA condition 10 µM of PNA was added during this 45-minute infection stage; during this time 8
the PNA is allowed to enter the Salmonella and subsequently be transported into the HeLa cell 9
as it infects via its T3SS. For the Naked-PNA condition 10 µM of PNA is added to the gentamicin 10 containing media that the HeLa cells are incubated in for 18 hours. Post 18 hours of treatment 11
HeLa cells are fixed for imaging or lysed for Colony forming Unit ( 
